Gilead hungers for more cancer drug deals

Gilead Sciences ($GILD) waves an active trigger finger for acquisitions. After loading up on cancer drugs through a number of deals in recent years, the biopharma powerhouse is looking for new targets, Bloomberg reported. And Gilead's interest in blood-cancer drugs sparked some speculation about a couple of likely buyout prospects. As the news service reported, Gilead has ponied up $1.2 billion...